Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea - Scorecard - MDSpire
Advertisement
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea
Clinical Scorecard: Interim Findings from a Three-Year Post-Marketing Study on the Use of Fremanezumab for Migraine Management in South Korean Patients
At a Glance
Category
Detail
Condition
Migraine
Key Mechanisms
Inhibition of calcitonin gene-related peptide (CGRP) and its receptor.
Target Population
Adults aged ≥ 18 years with a diagnosis of migraine.
Care Setting
Real-world clinical practice in South Korea.
Key Highlights
Fremanezumab was well tolerated, with ~18% experiencing mild side effects.
57% of participants achieved a ≥ 50% reduction in monthly migraine days after 12 weeks.
87% reported meaningful improvements on the Patient Global Impression of Change (PGIC) scale.
The study supports the use of fremanezumab as a preventive migraine treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of migraine as per International Classification of Headache Disorders, Third Edition criteria.
Management
Fremanezumab administered at approved dosing regimens of 225 mg monthly or 675 mg quarterly.
Monitoring & Follow-up
Monitor for adverse events and changes in migraine frequency using headache diaries.
Risks
Exclusion of participants with contraindications to fremanezumab.
Patient & Prescribing Data
Korean adults with episodic or chronic migraine.
Fremanezumab demonstrates a favorable safety profile and meaningful clinical benefits.
Clinical Best Practices
Ensure informed consent is obtained prior to participation.
Document all relevant data in electronic medical records.
Collect safety information telephonically if follow-up visits are missed.
